CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
Julian D. Gillmore(University of Auckland), David Lebwohl(Intellia Therapeutics (United States)), David E. Gutstein(Scripps Research Institute), Olivier Harari(Regeneron (United States)), Jonathan D. Phillips(University of Kentucky), Kristy Wood(University of Auckland), Michael L. Maitland(Virginia Cancer Institute), John P. Leonard(New York University), Randy Soltys(University of Auckland), Brian Zambrowicz(Regeneron (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Adam Amaral(University of Auckland), Christos A. Kyratsous(Regeneron (United States)), Andrew Murphy(Baker Heart and Diabetes Institute), Jörg Täubel(British Heart Foundation), Yuanxin Xu(Intellia Therapeutics (United States)), Kathryn Walsh(University of Auckland), Mark D. McKee(University of Auckland), Marianna Fontana(The Royal Free Hospital), Adam P. Boyd(University of Auckland), Daniel O’Connell(University of Auckland), Justin Kao(University of Auckland), Ed Gane(University of Auckland), Jessica Seitzer(Intellia Therapeutics (United States)), Jeffrey Cehelsky(Alnylam Pharmaceuticals (United States)), Andrew Schiermeier(University of Auckland)
Cited by 47
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k